Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Chief Legal Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,770 |
Reported balance
After 2026-08-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 4,485 · Balance 35,770 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:10 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,485 | $10.29 | $46,150.65 |
DisclosureSEC source: 0002081460-26-000009 · form4-08202026_040803.xml · nonDerivative · entry 1 Cho Esther · CIK 0002081460 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,770 F1 · shares: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0002081460-26-000004 · form4-02262026_040212.xml · derivative · entry 1 Cho Esther · CIK 0002081460 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-02-23 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 24, 2026 Filed Mar 27, 2026 20:15 UTC Amendment | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0002081460-26-000007 · form4a-03272026_040301.xml · derivative · entry 1 Cho Esther · CIK 0002081460 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-02-23 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,745 | $16.35 | $77,580.75 |
DisclosureSEC source: 0002081460-26-000002 · form4-02202026_040204.xml · nonDerivative · entry 1 Cho Esther · CIK 0002081460 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,755 F1 · shares: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.